A benefit-risk assessment of agomelatine in the treatment of major depression.
about
Personalized medicine in major depressive disorder -- opportunities and pitfallsAntidepressant efficacy of agomelatine: meta-analysis of published and unpublished studiesPharmacogenomics and Global Precision Medicine in the Context of Adverse Drug Reactions: Top 10 Opportunities and Challenges for the Next DecadeA systematic review of agomelatine-induced liver injuryAgomelatine in the treatment of major depressive disorder: an assessment of benefits and risksAgomelatine beyond borders: current evidences of its efficacy in disorders other than major depressionHepatotoxicity associated with agomelatine and other antidepressants: Disproportionality analysis using pooled pharmacovigilance data from the Uppsala Monitoring Centre.Comparison of agomelatine and selective serotonin reuptake inhibitors/serotonin-norepinephrine reuptake inhibitors in major depressive disorder: A meta-analysis of head-to-head randomized clinical trials.Therapeutic effects of melatonin receptor agonists on sleep and comorbid disorders.Drug-Induced Liver Injury Associated With Antidepressive Psychopharmacotherapy: An Explorative Assessment Based on Quantitative Signal Detection Using Different MedDRA Terms.Melatonin in aging and disease -multiple consequences of reduced secretion, options and limits of treatment.Risk analysis of use of different classes of antidepressants on subsequent dementia: A nationwide cohort study in Taiwan.Implementation of a reference-scaled average bioequivalence approach for highly variable generic drug products of agomelatine in Chinese subjects.The melatonergic system in mood and anxiety disorders and the role of agomelatine: implications for clinical practice.Psychotropic drugs and liver disease: A critical review of pharmacokinetics and liver toxicity.Cardiovascular effects of melatonin receptor agonists.Cardiovascular adverse effects of newer antidepressants.Current Phase II investigational therapies for insomnia.Excessive sweating induced by interaction between agomelatine and duloxetine hydrochloride: case report and review of the literature.Search for unpublished data by systematic reviewers: an audit.Agomelatine-induced hepatotoxicity.Agomelatine, melatonin and depressive disorder.Moclobemide as add-on therapy to agomelatine in a patient with treatment-resistant major depressive disorder: a psychopharmacological case.Agomelatine: a new option for treatment of depression?Agomelatine-induced gynaecomastia.Neurobiology, pathophysiology, and treatment of melatonin deficiency and dysfunction
P2860
Q24170133-3ADF0E8B-E9E2-4808-8E47-2CFEECB40B59Q28236293-274426DA-B082-412B-A4D2-FAE587693773Q28392069-BE4AA539-9979-4B70-A93B-701525A5F449Q28648515-1CE95EFE-78BA-4EEC-9E56-BA0A27E3BE81Q28651497-F254065E-DC49-4B60-A4F1-EE9C1B8232E2Q28651498-02D7849F-6433-417E-A738-513F42704F46Q30887490-E07653C1-BF59-4073-B616-D7CB4320B65EQ34040072-C90282F8-09DD-4EE3-8463-556A5117543FQ34358480-EBEF8BBE-4F0E-4EBD-B656-986CFAE05548Q35809210-B0A86BEB-32D6-4D16-AA9F-846B236B8EB7Q36040915-08BCF2C9-2A70-4808-B51F-0A9BE684548FQ36338197-79B29CAD-C72C-4CF7-A95D-8F94CF832DE9Q36495583-EFC3102C-5326-4A84-8713-5FCFEF98BCFFQ37007350-6F95C128-F0A5-4784-91CF-DD16677EE7F6Q37625519-F924C46F-71E6-4974-8541-D9A779BA8797Q38037124-F9D301E3-FA08-4679-829D-0BD30E84820EQ38205025-EAC9E53D-4AEF-473D-985C-49C2A8826F8AQ38271292-87D9FF33-F7B1-41DC-B7FE-D92EC85CCEBBQ38313416-63A2DB8F-EFDE-48EB-92F6-6B26DBEBE0C9Q42376820-2D1A61AF-FB97-45FE-BEF1-37859B32563EQ45748567-50480DA8-AFDC-45E5-8854-40A75C4EFDBDQ46936791-D86935CB-9293-42CA-864E-FF049F412C5BQ48074026-FCFB5C40-054A-4585-9EFE-053F1027B742Q48375336-8B33F556-D13A-41E7-B6D9-12A718AC685DQ48446417-9D0C0C1D-24A8-479C-BD6C-6A096F75395FQ58914961-996A9EC0-7E41-4B54-9B1B-DEB26CFF556B
P2860
A benefit-risk assessment of agomelatine in the treatment of major depression.
description
2011 nî lūn-bûn
@nan
2011 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
A benefit-risk assessment of agomelatine in the treatment of major depression.
@ast
A benefit-risk assessment of agomelatine in the treatment of major depression.
@en
A benefit-risk assessment of agomelatine in the treatment of major depression.
@nl
type
label
A benefit-risk assessment of agomelatine in the treatment of major depression.
@ast
A benefit-risk assessment of agomelatine in the treatment of major depression.
@en
A benefit-risk assessment of agomelatine in the treatment of major depression.
@nl
prefLabel
A benefit-risk assessment of agomelatine in the treatment of major depression.
@ast
A benefit-risk assessment of agomelatine in the treatment of major depression.
@en
A benefit-risk assessment of agomelatine in the treatment of major depression.
@nl
P2860
P1433
P1476
A benefit-risk assessment of agomelatine in the treatment of major depression.
@en
P2860
P304
P356
10.2165/11593960-000000000-00000
P577
2011-09-01T00:00:00Z
P6179
1008336932